Clinical trials: sponsored by European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access
SPECTAmel is a standardized, quality-assured molecular screening platform for tumor characterization and storage of human biological material (HBM) for the purpose of integrating new biomarkers into clinical trials and optimizing…
- Trial name
- NCT02507947
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastrointestinal Stromal Tumor
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after surgery may kill any remaining tumor cells.
- Trial name
- NCT00103168
- Testing
- imatinib mesylate
- Where
- 50 sites in Australia, Denmark and 4 more
- Volunteers
- 908 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma of Unknown Primary
Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00047125
- Testing
- radiation therapy
- Where
- 262 sites in United States, Belgium and 4 more
- Volunteers
- 600 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides
RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy is more effective with or without bexarotene in…
- Trial name
- NCT00056056
- Testing
- bexarotene, methoxypsoralen, UV light therapy
- Where
- 28 sites in Austria, Belgium and 11 more
- Volunteers
- 93 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01019434
- Testing
- temozolomide, temsirolimus
- Where
- 13 sites in Belgium, France and 6 more
- Volunteers
- 111 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003888
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 44 sites in Austria, Belgium and 13 more
- Volunteers
- 359 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00074087
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 11 sites in Austria, Germany and 4 more
- Volunteers
- 49 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Squamous Cell of Head and Neck
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck
The general objectives are to evaluate the pre-operative activity and the safety of afatinib in head and neck cancer and to explore the different downstream molecular pathways to identify tumor response and resistance mechanisms.
- Trial name
- NCT01538381
- Testing
- Afatinib, Observation
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002839
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 20 sites in Belgium, France and 4 more
- Volunteers
- 564 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498953
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00646659
- Testing
- cetuximab, carboplatin, cisplatin
- Where
- Belgium
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Lenalidomide Maintenance Post-debulking in Advanced CTCL
RATIONALE: Observation is watching a patient's condition but not giving treatment unless symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT01098656
- Testing
- lenalidomide
- Where
- 22 sites in Austria, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Drug Induced Interstitial Lung Disease (DIILD) Cancer Patients
Imaging Biomarker in Cancer Drug Induced ILD
Drug induced interstitial lung disease (DIILD) is caused by iatrogenic injury to the lung parenchyma and can be caused by over four hundred different drugs in humans.
- Trial name
- ImageILD (NCT03294746)
- Testing
- Clinical evaluations, Thoracic CT
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Lymphoma
Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Collecting and storing samples of tumor tissue, blood, bone marrow, and other body fluids from patients to test in the laboratory and collecting information about the patient's health and treatment may help doctors…
- Trial name
- NCT01185886
- Testing
- gene expression analysis, mutation analysis, polymorphism analysis
- Where
- 21 sites in Belgium, France and 1 more
- Volunteers
- 1,200 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide and carmustine, work in different ways to stop tumor cells from dividing…
- Trial name
- NCT00086879
- Testing
- carmustine, erlotinib hydrochloride, temozolomide
- Where
- 10 sites in Belgium, France and 3 more
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma…
- Trial name
- NCT00091572
- Testing
- Temozolomide, Dacarbazine
- Volunteers
- 859 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophagogastric Adenocarcinoma, Metastatic Disease
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)
This is a prospective, multicenter, randomized, placebo-controlled, triple-blind phase II trial. The randomization will be a 1:1 randomization (experimental arm:control arm).
- Conditions
- Esophagogastric Adenocarcinoma, Metastatic Disease, No Previous Chemotherapy for Metastatic Esophagogastric Cancer
- Trial name
- MEGAN (NCT02856867)
- Testing
- Nintedanib, Fluorouracil, Leucovorin
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer Metastatic, Liver Metastases
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases, resection should be…
- Conditions
- Colorectal Cancer Metastatic, Liver Metastases, KRAS Mutated Colorectal Cancer
- Trial name
- BOS3 (NCT01646554)
- Testing
- Modified FOLFOX6, Aflibercept, Surgery
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer
The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic…
- Trial name
- HERA (NCT00045032)
- Testing
- Herceptin
- Where
- 203 sites in Argentina, Australia and 31 more
- Volunteers
- 5,099 people
- Sponsor
- Hoffmann-La Roche